Cingulate
Market cap $70.6M 15.0M shares (10-Q, Nov 13, 2026) × $4.72 close Nov 17, 2026
Most recent annual filing: 2026-03-18
Pipeline (1 active programs)
Technology platforms
PTR · BDD Pharma
Precision Timed Release (PTR) drug delivery platform — proprietary multi-core tablet technology incorporating an Erosion Barrier Layer (EBL) to deliver precisely timed pulsatile drug releases; focus areas: ADHD and anxiety disorders. EBL formulation (Oralogik) licensed from BDD Pharma.
Precision Timed Release
PTR-enabled tri-modal release delivery platform for oral tablets; designed to provide morning onset and sustained active-day coverage in a single once-daily tablet; focus area: ADHD and potentially other CNS conditions
Precision Timed Release · BDD Pharma
PTR drug delivery platform incorporating a proprietary Erosion Barrier Layer (EBL) to control drug release at precise, pre-defined times; designed to enable true once-daily dosing; focus areas include ADHD and anxiety disorders. EBL formulation (Oralogik) licensed from BDD Pharma.
PTR
Precision Timed Release drug delivery platform incorporating a proprietary Erosion Barrier Layer for release of drug substance at specific, pre-defined time intervals, enabling once-daily multi-dose tablets; focus areas include ADHD and anxiety
Capital (as filed)
- Cash
- $23.2M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$7.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $23.2M cash, runway mid-2027 per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (8)
- 2026-11-17 UPDATE: Cingulate (CING) - A Second Salesman for the ATM 🔒 Paid
- 2026-11-11 UPDATE: Cingulate (CING) - The Resubmission Finally Gets a Date (But Not a Class) 🔒 Paid
- 2026-08-14 UPDATE: Cingulate (CING) - The Resubmission Nobody Will Date 🔒 Paid
- 2026-06-02 UPDATE: Cingulate (CING) - The CRL Lands, the Tripwire Arms 🔒 Paid
- 2026-05-15 UPDATE: Cingulate (CING) - The CMC Shoe Drops 17 Days Before PDUFA
- 2026-04-05 UPDATE: Cingulate (CING) - Institutional Adult Supervision Enters the Boardroom 🔒 Paid
- 2026-03-28 UPDATE: Cingulate (CING) - The Dilution Gap Just Became a Chasm 🔒 Paid
- 2026-03-23 Cingulate (CING) - Scientific Deep Dive on CTx-1301 and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (8 calls)
Every verdict Biotech Distilled has published on Cingulate, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-03-23 Watch Cingulate (CING) - Scientific Deep Dive on CTx-1301 and Pipeline Products Strong pharmacokinetic science but manufacturing risk from CDMO Form 483 and severe balance sheet risks make the stock too opaque to buy ahead of the May 31 PDUFA date.
- 2026-03-28 Avoid UPDATE: Cingulate (CING) - The Dilution Gap Just Became a Chasm The $100M ATM, Lincoln Park equity facility, and failed shareholder vote create a structural dilution ceiling that makes the equity a trap regardless of the underlying science.
- 2026-04-05 Avoid UPDATE: Cingulate (CING) - Institutional Adult Supervision Enters the Boardroom Falcon Creek's board seat provides slight oversight on dilution management but does not change the fundamental Sell/Avoid stance given the balance sheet minefield.
- 2026-05-15 Avoid UPDATE: Cingulate (CING) - The CMC Shoe Drops 17 Days Before PDUFA FDA's formal CMC information request buried in the 10-Q, a 64% share count explosion, and the Avondale CRL tripwire materially raise the probability of a PDUFA extension or CRL, reaffirming Sell/Avoid.
- 2026-06-02 Avoid UPDATE: Cingulate (CING) - The CRL Lands, the Tripwire Arms The FDA issued a CRL on CMC grounds, the Avondale deferral right is extinguished, and the toxic debt tripwire is now armed, validating the equity trap thesis.
- 2026-08-14 Watch UPDATE: Cingulate (CING) - The Resubmission Nobody Will Date Going-concern cliff pushed to mid-2027 and a wholly-owned U.S. patent to 2042 improve survival probability and M&A appeal enough to upgrade from Avoid to Watch, but no resubmission date and doubled share count keep it event-driven only.
- 2026-11-11 Watch UPDATE: Cingulate (CING) - The Resubmission Finally Gets a Date (But Not a Class) A December 2026–January 2027 resubmission window is real progress but the missing Class 1/2 designation and Q3 2027 launch guidance implying the slower 6-month clock running into the cash wall keep the stance at Watch.
- 2026-11-17 Watch UPDATE: Cingulate (CING) - A Second Salesman for the ATM Adding Maxim as a second ATM agent signals more dilutive share sales ahead of the resubmission classification, downgrading financial conviction further but keeping Watch as the Class 1/2 call still drives the outcome.
- Avoid call · opened Mar 30, 2026 at $5.84 · closed Aug 14, 2026 (downgraded to WATCH from avoid) at $5.09 · -12.8% vs XBI +32.5%
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (42)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 14, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 13, 2026ReleaseCingulate Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory Update on CTx-1301 NDA Resubmission
- Nov 13, 20268-KCurrent report: material agreement, results of operations · EX-99.1
- Nov 13, 2026424B3Prospectus (resale / update)
- Nov 13, 202610-QQuarterly report
- Nov 10, 2026ReleaseShane Schaffer, Cingulate Chairman and CEO, Provides Update on CTx-1301 in Interview with Innovators with Jane King→ BD updateSummary on the 8-K
- Nov 10, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateCingulate finally puts a date on the CTx-1301 resubmission — December 2026 to January 2027 — and says manufacturing work is "substantially completed," moving the story from indefinite to calendared; a Q3 2027 commercial launch target follows, but the Class 1 vs. Class 2 FDA review clock remains undisclosed, keeping the approval date range wide.
- Oct 2, 20268-KCurrent report: officer / director change
- Sep 17, 2026ReleaseShane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma
- Aug 13, 2026ReleaseCingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readinessvia aggregatorBD extracted 1 program update from this document → CING pipeline
- Aug 13, 20268-KCurrent report: results of operations · EX-99.1
- Aug 13, 202610-QQuarterly report
- Aug 11, 2026ReleaseCingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic ProfileBD extracted 1 program update from this document → CING pipeline
- Jul 30, 2026ReleaseCingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
- Jul 23, 20268-KCurrent report: officer / director change
- Jul 14, 20268-KCurrent report: officer / director change, shareholder vote
- Jul 2, 2026ReleaseCingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
- Jul 2, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
- Jun 16, 2026ReleaseCingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
- Jun 16, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Jun 4, 2026ReleaseStonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26BD extracted 1 program update from this document → CING pipeline
- Jun 2, 2026ReleaseCingulate Receives Complete Response Letter from FDA for CTx-1301
- Jun 2, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1BD extracted 1 program update from this document → CING pipeline
- May 29, 2026DEFA14AProxy soliciting material
- May 29, 2026DEF 14AProxy statement
- May 19, 20268-KCurrent report: officer / director change
- May 14, 2026Release2026 2025 ArchiveBD extracted 1 program update from this document → CING pipeline
- May 14, 2026ReleaseCingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
- May 14, 20268-KCurrent report: results of operations · EX-99.1
- May 14, 202610-QQuarterly report
- Apr 28, 2026424B3Prospectus (resale / update)
- Apr 14, 2026S-3Shelf registration
- Apr 2, 20268-KCurrent report: officer / director change
- Mar 27, 2026424B3Prospectus (resale / update)
- Mar 26, 2026SCHEDULE 13D/A13D amendment
- Mar 24, 20268-KCurrent report: material agreement, shareholder vote
- Mar 24, 2026424B3Prospectus (resale / update)
- Mar 23, 2026S-3/AShelf registration (amended)
- Mar 20, 2026S-3Shelf registration
- Mar 18, 2026DEFA14AProxy soliciting material
- Mar 18, 20268-KCurrent report: results of operations, other events · EX-99.1
- Mar 18, 202610-KAnnual report
- Mar 2, 2026DEF 14AProxy statement
11 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Jul 15, 2026S-8Employee plan registration
- May 29, 2026ARSAnnual report to shareholders
- May 18, 2026PRE 14APRE 14A
- Apr 24, 2026EFFECTRegistration effective
- Apr 22, 2026CORRESPCORRESP
- Apr 17, 2026UPLOADUPLOAD
- Mar 26, 2026EFFECTRegistration effective
- Mar 26, 2026CORRESPCORRESP
- Mar 24, 2026UPLOADUPLOAD
- Mar 24, 2026EFFECTRegistration effective
- Mar 23, 2026CORRESPCORRESP